行情

GERN

GERN

杰龙公司
NASDAQ

实时行情|Nasdaq Last Sale

1.370
-0.030
-2.14%
盘后: 1.360 -0.01 -0.73% 18:46 11/14 EST
开盘
1.410
昨收
1.400
最高
1.420
最低
1.330
成交量
144.37万
成交额
--
52周最高
2.140
52周最低
0.9547
市值
2.74亿
市盈率(TTM)
-5.4866
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

GERN 新闻

  • Edited Transcript of GERN earnings conference call or presentation 7-Nov-19 1:00pm GMT
  • Thomson Reuters StreetEvents.4小时前
  • Geron: A Different Company
  • Seeking Alpha - Article.1天前
  • Geron: Hold Despite Slim Premium As Promising Trials Await Funding
  • Seeking Alpha - Article.2天前
  • Geron Corporation (Delaware) (GERN) Q3 2019 Earnings Call Transcript
  • MotleyFool.com.6天前

更多

所属板块

生物技术和医学研究
-0.05%
制药与医学研究
-0.27%

热门股票

名称
价格
涨跌幅

GERN 简况

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Janssen is engaged in the development of Imetelstat with two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity.
展开

Webull提供Geron Corporation的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。